Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders
出版年份 2023 全文链接
标题
Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders
作者
关键词
-
出版物
CLINICS IN LABORATORY MEDICINE
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-06-17
DOI
10.1016/j.cll.2023.05.003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee
- (2022) Elias Campo et al. BLOOD
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- (2022) Ruth M. de Tute et al. JOURNAL OF CLINICAL ONCOLOGY
- Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?
- (2022) Guldane Cengiz Seval et al. Frontiers in Oncology
- Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
- (2022) Juan-Jose Garcés et al. JOURNAL OF CLINICAL ONCOLOGY
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials
- (2022) Bruno Paiva et al. BLOOD
- Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
- (2022) Rosalinda Termini et al. CLINICAL CANCER RESEARCH
- Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
- (2022) David M Foureau et al. Clinical Lymphoma Myeloma & Leukemia
- Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy
- (2022) Qi Gao et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- GPRC5D-Targeted CAR T Cells for Myeloma
- (2022) Sham Mailankody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
- (2022) Kara-Louise Royle et al. BMJ Open
- Newly diagnosed multiple myeloma: making sense of the menu
- (2022) Caitlin L. Costello Hematology-American Society of Hematology Education Program
- Tailored Treatment to MRD Response: A Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using High Dose Twice‐Weekly Carfilzomib (45 and 56 mg/m 2 ) in Combination with Lenalidomide and Dexamethasone
- (2021) Neha Korde et al. AMERICAN JOURNAL OF HEMATOLOGY
- Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
- (2021) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE
- (2021) Jesus F. San-Miguel et al. BLOOD
- Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA
- (2021) Michele Cavo et al. BLOOD
- Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
- (2021) Renata Bezdekova et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
- (2021) Kenneth C. Anderson et al. CLINICAL CANCER RESEARCH
- Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma
- (2021) Joaquin Martinez-Lopez et al. Journal of Hematology & Oncology
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
- (2021) Benjamin Diamond et al. Lancet Haematology
- Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
- (2021) Moritz Binder et al. LEUKEMIA
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
- (2021) Carlos Fernández de Larrea et al. Blood Cancer Journal
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- (2021) Meera Mohan et al. Blood Advances
- CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
- (2020) Sabarinath V. Radhakrishnan et al. Nature Communications
- Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
- (2020) Benjamin T. Diamond et al. BLOOD REVIEWS
- Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry
- (2020) Aya Nakaya et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- High‐sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events
- (2020) Ulrike Sommer et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- CD319 ( SLAMF7 ) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab
- (2020) Kah Teong Soh et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
- (2020) María-Victoria Mateos et al. Blood Cancer Journal
- Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
- (2019) Luzalba Sanoja-Flores et al. BLOOD
- Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease
- (2019) Kah Teong Soh et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma
- (2018) Dalia A. Salem et al. LEUKEMIA RESEARCH
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
- (2018) Praful Ravi et al. Blood Cancer Journal
- Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
- (2017) Miquel Granell et al. HAEMATOLOGICA
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
- (2017) Juan-Jose Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
- (2017) O. Landgren et al. JOURNAL OF INTERNAL MEDICINE
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
- (2017) Miquel Granell et al. HAEMATOLOGICA
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma
- (2016) Daniel J. Royston et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Multicentric Castleman disease: Where are we now?
- (2016) Hao-Wei Wang et al. SEMINARS IN DIAGNOSTIC PATHOLOGY
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
- (2015) A. C. Rawstron et al. BLOOD
- Clinical features and prognostic factors in solitary plasmacytoma
- (2015) Paola Finsinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases
- (2015) Fanny Pojero et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
- (2015) Ola Landgren et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
- (2015) Maryalice Stetler-Stevenson et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma
- (2015) Juan Flores-Montero et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
- (2015) R. M. de Tute et al. HAEMATOLOGICA
- Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
- (2015) R. M. de Tute et al. HAEMATOLOGICA
- Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma
- (2014) B. Paiva et al. BLOOD
- Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method
- (2014) Elisabet E. Manasanch et al. LEUKEMIA & LYMPHOMA
- Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance
- (2013) D Zamarin et al. LEUKEMIA
- Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
- (2013) Prashant R. Tembhare et al. LEUKEMIA RESEARCH
- Angioimmunoblastic T-Cell Lymphoma Partially Obscured by an Epstein-Barr Virus–Negative Clonal Plasma Cell Proliferation
- (2012) Alison R. Huppmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started